• 정신신체의학
• /
• 제24권1호
• /
• pp.3-8
• /
• 2016

기능성 소화불량증은 우리나라 성인인구의 7.7%가 이환되어 있는 흔한 소화기 기능성질환이다. 주요 증상은 불편한 식후 충만감, 조기 포만감, 상복부 통증, 상복부 쓰림이다. 이런 증상들이 증상을 설명할 만한 기질적인 문제 없이 만성적으로 나타나는 질환이다. 기능성 소화불량증은 치명적이지는 않지만 대개 건강관련 삶의 질을 저하시키고 다른 소화기 기능성질환(위식도역류질환, 과민성 장증후군, 변비)과 공존할 때 더욱 불편함을 초래할 수 있다. 이러한 기능성 소화불량증과 다른 소화기 기능성질환과의 공존을 '중복 증후군'으로 칭한다. 중복 증후군 환자에서 불안, 신체화장애, 불면 등의 정신건강의학적인 문제가 보다 흔히 연관되어 있다. 그러므로 진료의는 소화불량을 호소하는 환자에게 다른 소화기 기능성질환이 공존하는지 여부를 파악하고, 기저 정신건강의학적 문제를 다루는 것이 필요하다. 기능성 소화불량증 환자에게 위약효과는 40% 안팎으로 매우 큰 편이며, 위약대비 효과가 증명된 위장관 운동촉진제는 네 가지이다. 간혹 이러한 위장관 운동 촉진제의 장기간 투약은 비가역적이거나 치명적인 부작용을 야기할 수 있으므로, 처방의사는 위장관 운동촉진제의 가능한 부작용과 연관된 위험인자를 숙지하고 있어야 한다. 병적 위산역류는 기능성 소화불량증 환자에게 드물지 않으며, 위산분비억제제는 많은 부분의 기능성 소화불량증 환자에게 위장관 운동촉진제 만큼 효과적이다.

• Pediatric Gastroenterology, Hepatology & Nutrition
• /
• 제11권sup1호
• /
• pp.30-37
• /
• 2008

The knowledge of motility disorders of the gastrointestinal tract has increased over the past decades. The development of newer therapies for bowel motility disorders has been disappointingly slow. Prokinetic agents are medications that enhance coordinated gastrointestinal motility and transit of material in the gastrointestinal tract. These agents are pharmacologically and chemically diverse. However, life-threatening adverse effects of prokinetic agents such as cisapride was present. In this review, pharmacologic effects and use of prokinetic agents in children was introduced.

• 한국식품영양학회지
• /
• 제10권2호
• /
• pp.186-192
• /
• 1997

성별, 직업, 성품, 생활양식이 전혀 다른 K43과 C45 환자의 위 내시경적 소견과 치료방법을 논의하였다. K43은 잘못된 식습관과 스트레스에 의한 미란성 위염환자로서 제산제와 함께 H2-수용체 길항제, H+/K+-pump 억제제, prostaglandin 제제, colloidal bismuth, sucralfate prokinetics 등 전통적인 약물에서부터 부작용을 감소시킨 최근에 개발된 약물에 이르기까지 효과가 인정된 약물들을 폭넓게 사용하였으나 증상을 개선치 못하였으며, 임상병리 검사와 상복부 초음파 검사는 정상이었으나, 소화생리기능 검사에서 visceral hypersensitivity를 나타내었다. 그러나 C45는 평소에 두통으로 NSAIDs를 습관적으로 복용한 경험에 의하여 발생되었을 것으로 추정되는 전형적인 위·십이지장 궤양의 환자로서 H. pylori 박멸제와 함께 일반적인 소화성 궤양의 치료제로 활동기에서 치유기로 증상을 크게 완화시켰다. 특히 K43은 amitryptyline을 투여하였으나 난치성 환자로 남아 있다. 이러한 원인불명의 비궤양 환자는 미국에서 해마다 15%씩 증가하는 추세에 있고 적절한 치료법도 없으며, 우리 나라에서는 통계치도 없는 실정인 점을 지적하고 싶다.

• Biomolecules & Therapeutics
• /
• 제21권3호
• /
• pp.181-189
• /
• 2013

Motilitone$^{(R)}$ (DA-9701) is a new herbal drug that was launched for the treatment of functional dyspepsia in December 2011 in Korea. The heterogeneous symptom pattern and multiple causes of functional dyspepsia have resulted in multiple drug target strategies for its treatment. DA-9701, a compound consisting of a combination of Corydalis Tuber and Pharbitidis Semen, has being developed for treatment of functional dyspepsia. It has multiple mechanisms of action such as fundus relaxation, visceral analgesia, and prokinetic effects. Furthermore, it was found to significantly enhance meal-induced gastric accommodation and increase gastric compliance in dogs. DA-9701 also showed an analgesic effect in rats with colorectal distension induced visceral hypersensitivity and an antinociceptive effect in beagle dogs with gastric distension-induced nociception. The pharmacological effects of DA-9701 also include conventional effects, such as enhanced gastric emptying and gastrointestinal transit. The safety profile of DA-9701 is also preferable to that of other treatments.

• 한국임상약학회지
• /
• 제7권1호
• /
• pp.22-32
• /
• 1997

The gastrointestinal disorders (GI disorders) is one of the most common diseases in Korea. The community pharmacists are often faced with the complaints of symptoms due to the GI disorders. However the drugs used to treat the GI disorders are frequently abused by the patients themselves because these drugs are easily available and have high placebo effects. Therefore, we have reviewed the digestive diseases statistics of 1996 to find out the frequencies of the GI disorders in the outpatients of Samsung Medical Center. Using these statistic data, we figured out the frequently diagnosed GI disorders and analysed commonly used prescriptions from February 1st to 28th of 1997. In addition, we also evaluated the commonly used drugs in these prescriptions. About twenty thousands of patients visited the hopital because of their GI symptoms in 1996. It was found that dyspepsia, viral hepatitis, and gastric and duodenal ulcer disease are frequently diagnosed in these patients. In a point of view on other GI disorders, gastritis and duodenitis, irritable bowel syndrome, gastroesophageal reflux disease, constipation and diarrhea were commonly detected. And a number of drugs were prescribed to treat the GI disorders, which included the prokinetics, Histamine-2 receptor antagonists, proton pump inhibitor, antacids, tranquillizers, antidepressants, antispasmodics, laxatives and so on. Interestingly, there were many prescriptions composing of the antibiotic regimens to eradicate H. pylori which has been proven to cause peptic ulcers.

• 한국임상수의학회지
• /
• 제38권5호
• /
• pp.231-234
• /
• 2021

A 14-month-old, intact female Maltese (case 1) and a 26-month-old, spayed female Dachshund (case 2) had persistent regurgitation over 1 year and 2 years, respectively. In both cases, there were not specific findings in blood examination. Diagnostic imaging and fluoroscopy revealed that gastroesophageal reflux (GER) occurred when the patients ate a barium meal without abdominal contraction. They were treated with proton-pump inhibitor (esomeprazole), sucralfate and prokinetics (cisapride) while in a standing position for an hour after every meal, according to the gastroesophageal disease (GERD) suggested treatment. The case 1 dog was discharged with improved clinical signs, and the case 2 dog also had been improved clinical signs; however, aspiration pneumonia occurred in case 2, which was thought to be a complication from GERD. After receiving treatment for aspiration pneumonia, the case 2 dog was discharged from the hospital. Since there was no further improvement in symptoms after discharge, the case 1 dog was euthanized by owner's request, and the case 2 is alive, having only mild clinical signs upon the writing of this paper.

• Pediatric Gastroenterology, Hepatology & Nutrition
• /
• 제25권4호
• /
• pp.300-311
• /
• 2022

Purpose: Dysphagia, vomiting and feeding difficulties are common symptoms, with which children present. Esophageal function testing with high resolution manometry can help in diagnosing and treating these patients. We aim to access the clinical utility of high-resolution manometry of esophagus in symptomatic pediatric patients. Methods: A retrospective chart review was done on all symptomatic patients who underwent esophageal high-resolution manometry between 2010 and 2019 at Sydney Children's Hospital, Australia. Manometry results were categorized based on Chicago classification. Demographic data, indication of procedure, manometric findings, and details of treatment changes were obtained and analyzed. Results: There were 62 patients with median age of 10 years (9 months-18 years). The main indication for the procedure was dysphagia (56%). Thirty-two percent of patients had a co-morbid condition, with esophageal atresia accounting for 16%. The majority (77%) of patients had abnormal manometry which included, ineffective esophageal motility in 45.2%. In esophageal atresia cohort, esophageal pressurization was seen in 50%, aperistalsis in 40% and 10% with prior fundoplication had esophago-gastric junction obstruction. Patients with esophago-gastric junction obstruction or achalasia were treated by either pneumatic dilation or Heller's myotomy. Patients with ineffective esophageal motility and rumination were treated with a trial of prokinetics/dietary texture modification and diaphragmatic breathing. Conclusion: Esophageal high-resolution manometry has a role in the evaluation of symptomatic pediatric patients. The majority of our patients had abnormal results which led to change in treatments, with either medication, surgery and/or feeding modification with resultant improvement in symptoms.

• 대한기관식도과학회지
• /
• 제10권2호
• /
• pp.22-27
• /
• 2004

Background : LPRD(Laryngopharyngeal reflux disease) gives rise to inflammatory change in the pharyngolaryngeal tissue with various otolaryngologic symptoms. Ranitidine, histamine H2receptor antagonists, are currently used as therapeutic medications. However, the efficacy of Ranitidine on LPRD has not been proven yet. Objectives : We intended to analyze the efficacy of the Ranitidine on LPRD. Materials :md Methods : In 20 multicenter, 607 patients with LPR(laryngopharyngeal reflux) symptom were observed to evaluate their symptoms and laryngoscopic findings after 4 weeks, 8 weeks, and 12 weeks of treatment of Ranitidine. Results : The symptom of LPR including globus sensation, sore throat hoarseness, regurgitatioin are improved after 4 weeks $86.2\%,\;8 weeks\;91.5\%,\;12 weeks\;92.9\%$ of Ranitidine treatment and improved after 4 weeks $91.5\%,\;8 weeks\;94.5\%,\;12 weeks\; 97.2\%$ of Ranitidine combined with prokinetics. The rates of sore throat, chronic cough, globus sensation improvement at 8 weeks after treatment are $26.7\%,\;16.7\%,\;16\%$. Conclusion : In patient with LPR, Ranitidine treatment reduces LPR symptoms very effectively.

• 대한후두음성언어의학회지
• /
• 제20권2호
• /
• pp.141-147
• /
• 2009

Background and Objectives: Although laryngopharyngeal reflux disease (LPRD) is a widely recognized disease in the field of otolaryngology, controversies still exist regarding the diagnosis and treatment for it. The purpose of this survey was to find out current trends in diagnosis and management of LPRD among Korean otolaryngologists. Materials and Method: Questionnaires were obtained from 26 Korean otolaryngology specialists by electronic balloting, and 46 members of the Korean Society of Head and Neck Surgery (KSHNS) bye-mail. Survey participants were asked about their preferences in diagnostic policy, duration/dosage of antireflux treatment, and their familiarity to the reflux symptom index (RST) and the reflux finding scores (RFS). Results: The majority of the survey participants (64%) preferred empiric therapy trial with proton pump inhibitors (PPIs) based on patients' symptoms and their laryngeal findings. PPIs alone (27%) or PPIs with prokinetics (32%) were usually prescribed as a first line treatment mostly with once daily schedule in the morning before meal and for less than 4 months of duration (86%). More than 90% of participants were aware of the RSI and RFS, but less than 50% of them were actually using those items in the clinics. Conclusion: Most of Korean otolaryngologists who participated in this survey answered that they prefer starting empirical treatments with proton pump inhibitors mainly based on the patient's symptoms and their laryngeal findings.

• 한국임상약학회지
• /
• 제25권4호
• /
• pp.254-263
• /
• 2015

Objectives: The present study assessed the prevalence of the potentially inappropriate medication (PIM) use in Korean elderly patients with Parkinson's disease. In addition, this study examined risk factors that affect PIM use. Method: A retrospective, observational study was conducted using Korean National Health Insurance claims database of 2009. PIM use in Parkinson's disease patients aged 65 years or older was examined based on 2012 Beers Criteria. Multivariable logistic regression was conducted to identify risk factors for PIM use. Results: Among 5,277 elderly patients with Parkinson's disease, 88.9% of patients used PIM(s) at least once. The average number of PIM items used per patient was 4.2. PIM use ratio, the proportion of total amount of PIMs to all medications per patient, was 12.6%. Frequently used PIM therapeutic classes were benzodiazepines (32.7%), first-generation antihistamines (19.2%), and prokinetics (17.5%). Individual PIMs most commonly used included chlorpheniramine (11.4%), levosulpiride (10.9%), diazepam (9.0%), and alprazolam (7.6%). Women (odds ratio [OR] 1.14, 95% confidence interval [CI] 1.11-1.16), medical aid (OR 1.18, 95% CI 1.15-1.21), and long-term facilities (OR 2.43, 95% CI 2.22-2.65) were shown to be risk factors associated with PIM use. Of particular, wide variation in PIM use was associated with the types of healthcare facility. Conclusion: The PIM prevalence was very high in elderly Parkinson's disease patients. Nationally effective and systematic efforts to identify and prevent PIM use should be made to ensure patient safety and to improve quality of care in the elderly.